ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.

ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC. specializes in end-to-end research and development services for biotechnology and life sciences, with deep expertise in clinical trial planning, execution, and regulatory-compliant study design. The company supports complex biomedical research initiatives, including Phase I healthy volunteer and special population studies, antigen-sparing vaccine evaluations, and neurosyphilis clinical investigations. Their technical capabilities span infectious disease therapeutics, immunological assay development, clinical operations, and data-driven trial management, with a focus on delivering scalable solutions for government-funded biomedical innovation. A key differentiator is their proven ability to manage multi-site clinical networks and execute high-stakes trials under stringent federal oversight, particularly for vaccine and biologic development programs. The contractor maintains a strong, sustained relationship with the Department of Health and Human Services, primarily supporting the National Institutes of Health and its institutes such as NIAID on critical public health initiatives. They also provide specialized R&D support to the Department of Defense for military medical research and have engaged with the General Services Administration through omnibus contracting vehicles to deliver scientific consulting services. Their agency engagements reflect a pattern of repeat work on mission-critical, long-term research programs requiring regulatory precision and operational scalability. Their industry focus centers on NAICS 541714 and 541715, which encompass non-nanotechnology biotechnology R&D and broader life sciences research, respectively. This positions them as a niche provider of clinical and translational research services within the federal biodefense, infectious disease, and vaccine development markets. They operate as a small business with a 2L entity structure, headquartered in Blue Bell, Pennsylvania, and serve federal clients nationwide without formal government certifications. Their market positioning is defined by technical rigor in clinical trial execution and a proven track record supporting high-impact public health and defense research objectives.